Lung cancer rebiopsy study aims to uncover immunotherapy resistance

NCT ID NCT04300062

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study collects tumor samples from 50 lung cancer patients whose disease has worsened while on immunotherapy. The goal is to analyze the tissue for clues about why the treatment stopped working. No new drug is being tested; instead, researchers hope to better understand resistance mechanisms to guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could reveal why some lung cancers stop responding to immunotherapy, pointing toward better treatments in the future.
What could go wrong: This is an observational study, not a treatment trial. It is small (50 participants) and early-stage, so findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression lung cancer lung neoplasm non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
RECRUITING

Boulogne-Billancourt, 92100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.